- Home
- S vs BLCO Comparison
S vs BLCO Comparison
Compare S & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- S
- BLCO
- Stock Information
- Founded
- S 2013
- BLCO 1853
- Country
- S United States
- BLCO Canada
- Employees
- S N/A
- BLCO N/A
- Industry
- S EDP Services
- BLCO Ophthalmic Goods
- Sector
- S Technology
- BLCO Health Care
- Exchange
- S Nasdaq
- BLCO Nasdaq
- Market Cap
- S 5.9B
- BLCO 5.2B
- IPO Year
- S 2021
- BLCO 2022
- Fundamental
- Price
- S $17.17
- BLCO $16.02
- Analyst Decision
- S Buy
- BLCO Hold
- Analyst Count
- S 28
- BLCO 14
- Target Price
- S $24.11
- BLCO $16.46
- AVG Volume (30 Days)
- S 5.0M
- BLCO 464.2K
- Earning Date
- S 12-03-2025
- BLCO 10-29-2025
- Dividend Yield
- S N/A
- BLCO N/A
- EPS Growth
- S N/A
- BLCO N/A
- EPS
- S N/A
- BLCO N/A
- Revenue
- S $907,381,000.00
- BLCO $4,976,000,000.00
- Revenue This Year
- S $24.41
- BLCO $8.12
- Revenue Next Year
- S $20.84
- BLCO $5.81
- P/E Ratio
- S N/A
- BLCO N/A
- Revenue Growth
- S 25.39
- BLCO 6.23
- 52 Week Low
- S $15.36
- BLCO $10.45
- 52 Week High
- S $29.29
- BLCO $20.71
- Technical
- Relative Strength Index (RSI)
- S 49.16
- BLCO 61.43
- Support Level
- S $16.05
- BLCO $14.89
- Resistance Level
- S $17.97
- BLCO $16.00
- Average True Range (ATR)
- S 0.53
- BLCO 0.50
- MACD
- S -0.02
- BLCO 0.04
- Stochastic Oscillator
- S 58.90
- BLCO 98.98
About S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.